GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (NAS:RVMD) » Definitions » Pretax Margin %

Revolution Medicines (Revolution Medicines) Pretax Margin % : -21,724.26% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Revolution Medicines's Pre-Tax Income for the three months ended in Dec. 2023 was $-161.19 Mil. Revolution Medicines's Revenue for the three months ended in Dec. 2023 was $0.74 Mil. Therefore, Revolution Medicines's pretax margin for the quarter that ended in Dec. 2023 was -21,724.26%.

The historical rank and industry rank for Revolution Medicines's Pretax Margin % or its related term are showing as below:

RVMD' s Pretax Margin % Range Over the Past 10 Years
Min: -3798.71   Med: -444.54   Max: -103.99
Current: -3798.71


RVMD's Pretax Margin % is ranked worse than
84.81% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs RVMD: -3798.71

Revolution Medicines Pretax Margin % Historical Data

The historical data trend for Revolution Medicines's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines Pretax Margin % Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -103.99 -252.50 -636.58 -704.14 -3,798.71

Revolution Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -369.41 -970.89 -2,570.55 - -21,724.26

Competitive Comparison of Revolution Medicines's Pretax Margin %

For the Biotechnology subindustry, Revolution Medicines's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Pretax Margin % falls into.



Revolution Medicines Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Revolution Medicines's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-439.891/11.58
=-3,798.71 %

Revolution Medicines's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-161.194/0.742
=-21,724.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revolution Medicines  (NAS:RVMD) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Revolution Medicines Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines (Revolution Medicines) Business Description

Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Executives
Stephen Michael Kelsey officer: See Remarks C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Jeff Cislini officer: General Counsel C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Mark A Goldsmith director, officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Margaret A Horn officer: See Remarks 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jack Anders officer: Chief Financial Officer C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barbara Weber director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Xiaolin Wang officer: See Remarks C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Thilo Schroeder director C/O NEXTECH INVEST LTD., BAHNHOFSTRASSE 18, ZURICH V8 8001
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Sushil Patel director C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK, THIRD FLOOR, WOBURN MA 01801
Third Rock Ventures Iii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Flavia Borellini director C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Third Rock Ventures Ii, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Peter Svennilson director, 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Vincent A. Miller director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139